or Try an Advanced Search...

    Technical Analysis for KPTI - Karyopharm Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 1.02 -7.27% -0.08
    KPTI closed down 7.27 percent on Wednesday, May 8, 2024, on 2.11 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical KPTI trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    200 DMA Resistance Bearish 0.00%
    Expansion Breakdown Bearish Swing Setup 0.00%
    Reversal New Lows Setup Bearish Swing Setup 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Earnings Movers Other 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -7.27%
    Older End-of-Day Signals for KPTI ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 12 hours ago
    Down 3% about 12 hours ago
    Down 2 % about 12 hours ago
    Fell Below 10 DMA about 12 hours ago
    10 DMA Support about 13 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    KPTI Chart by TradingView
    Basic chart:

    Profile

    Karyopharm Therapeutics Inc. Description

    Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Cancer Pharmaceutical Disease Treatment Of Cancer Oncology Lymphoma Chemotherapy Occupational Safety And Health Dog Stage Pharmaceutical Antibody Drug Conjugate

    Is KPTI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
    May 8 Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
    May 8 Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript
    May 8 Karyopharm announces significant refinancing transactions
    May 8 Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review
    May 8 Karyopharm Therapeutics GAAP EPS of -$0.32 beats by $0.03, revenue of $33.13M misses by $1.34M
    May 8 Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
    May 8 Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
    May 7 Karyopharm Therapeutics Q1 2024 Earnings Preview
    May 2 Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
    See more KPTI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.76
    52 Week Low 0.6174
    Average Volume 1,247,941
    200-Day Moving Average 1.16
    50-Day Moving Average 1.29
    20-Day Moving Average 1.14
    10-Day Moving Average 1.08
    Average True Range 0.12
    RSI (14) 39.76
    ADX 9.93
    +DI 16.01
    -DI 20.43
    Chandelier Exit (Long, 3 ATRs) 1.05
    Chandelier Exit (Short, 3 ATRs) 1.39
    Upper Bollinger Bands 1.33
    Lower Bollinger Band 0.95
    Percent B (%b) 0.19
    BandWidth 33.45
    MACD Line -0.06
    MACD Signal Line -0.06
    MACD Histogram 0.0007
    Fundamentals Value
    Market Cap 116.82 Million
    Num Shares 115 Million
    EPS -1.31
    Price-to-Earnings (P/E) Ratio -0.78
    Price-to-Sales 1.19
    Price-to-Book 12.05
    PEG Ratio -0.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.29
    Resistance 3 (R3) 1.32 1.26 1.25
    Resistance 2 (R2) 1.26 1.19 1.25 1.23
    Resistance 1 (R1) 1.14 1.15 1.11 1.11 1.21
    Pivot Point 1.08 1.08 1.07 1.07 1.08
    Support 1 (S1) 0.96 1.01 0.93 0.93 0.83
    Support 2 (S2) 0.90 0.97 0.89 0.81
    Support 3 (S3) 0.78 0.90 0.80
    Support 4 (S4) 0.75